JP2023521180A5 - - Google Patents
Info
- Publication number
- JP2023521180A5 JP2023521180A5 JP2022562062A JP2022562062A JP2023521180A5 JP 2023521180 A5 JP2023521180 A5 JP 2023521180A5 JP 2022562062 A JP2022562062 A JP 2022562062A JP 2022562062 A JP2022562062 A JP 2022562062A JP 2023521180 A5 JP2023521180 A5 JP 2023521180A5
- Authority
- JP
- Japan
- Prior art keywords
- brd9
- inhibitor
- brd9 inhibitor
- inhibitor according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063007161P | 2020-04-08 | 2020-04-08 | |
| US63/007,161 | 2020-04-08 | ||
| PCT/US2021/026223 WO2021207387A1 (en) | 2020-04-08 | 2021-04-07 | Use of bromodomain inhibitors for treatment of huntington's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521180A JP2023521180A (ja) | 2023-05-23 |
| JP2023521180A5 true JP2023521180A5 (enExample) | 2024-04-11 |
Family
ID=75660409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562062A Pending JP2023521180A (ja) | 2020-04-08 | 2021-04-07 | ハンチントン病の治療のためのブロモドメイン阻害剤の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230149373A1 (enExample) |
| EP (1) | EP4132520A1 (enExample) |
| JP (1) | JP2023521180A (enExample) |
| KR (1) | KR20230023615A (enExample) |
| CN (1) | CN115666562B (enExample) |
| AU (1) | AU2021254396A1 (enExample) |
| BR (1) | BR112022020392A2 (enExample) |
| CA (1) | CA3175916A1 (enExample) |
| IL (1) | IL296984A (enExample) |
| MX (1) | MX2022012632A (enExample) |
| WO (1) | WO2021207387A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300507B (zh) * | 2022-08-23 | 2024-03-01 | 杭州天玑济世生物科技有限公司 | I-brd9作为arih1激动剂的用途 |
| CN116143787B (zh) * | 2023-02-21 | 2024-11-29 | 烟台皓元生物医药科技有限公司 | 一种tp-472中间体及其制备方法和应用 |
| CN116942818B (zh) * | 2023-02-24 | 2025-09-02 | 中南大学 | 以brd7为靶点在制备肥胖相关精神疾病药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3450571B1 (en) * | 2014-02-24 | 2023-04-05 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
| CA3013988A1 (en) * | 2016-02-15 | 2017-08-24 | Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh | Taf1 inhibitors for the therapy of cancer |
| US11285218B2 (en) * | 2016-06-23 | 2022-03-29 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use |
| WO2019023149A1 (en) * | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| CN109568307A (zh) * | 2017-09-29 | 2019-04-05 | 中国科学院上海药物研究所 | 一类环状内酯类化合物在制备用于预防和/或治疗亨廷顿病的药物中的用途 |
| US20210198629A1 (en) * | 2018-08-20 | 2021-07-01 | University Of Georgia Research Foundation, Inc. | Compositions and methods for increasing beiging of white adipose tissue |
-
2021
- 2021-04-07 IL IL296984A patent/IL296984A/en unknown
- 2021-04-07 CA CA3175916A patent/CA3175916A1/en active Pending
- 2021-04-07 BR BR112022020392A patent/BR112022020392A2/pt unknown
- 2021-04-07 KR KR1020227038897A patent/KR20230023615A/ko active Pending
- 2021-04-07 JP JP2022562062A patent/JP2023521180A/ja active Pending
- 2021-04-07 WO PCT/US2021/026223 patent/WO2021207387A1/en not_active Ceased
- 2021-04-07 MX MX2022012632A patent/MX2022012632A/es unknown
- 2021-04-07 CN CN202180037352.2A patent/CN115666562B/zh active Active
- 2021-04-07 AU AU2021254396A patent/AU2021254396A1/en active Pending
- 2021-04-07 US US17/917,337 patent/US20230149373A1/en active Pending
- 2021-04-07 EP EP21721354.5A patent/EP4132520A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017075173A5 (enExample) | ||
| JP2021098728A5 (enExample) | ||
| JP2022191257A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| EP1651195A4 (en) | PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| JP2005500357A5 (enExample) | ||
| JP2021529829A5 (enExample) | ||
| JP2003503454A5 (enExample) | ||
| JP2017530163A5 (enExample) | ||
| JP2024512425A5 (enExample) | ||
| JP2015517528A5 (enExample) | ||
| JP2017511377A5 (enExample) | ||
| JPWO2023195530A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| JP2005507892A5 (enExample) | ||
| JP2018531929A5 (enExample) | ||
| JP2024541569A5 (enExample) | ||
| JP2024520132A5 (enExample) | ||
| JP2022539185A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2022552520A5 (enExample) | ||
| JP2023531930A5 (enExample) | ||
| JP2020527138A5 (enExample) | ||
| JP2005513036A5 (enExample) | ||
| RU2006131553A (ru) | Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap |